TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

Intangible Assets

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Note 8 - Intangible Assets

Intangible assets as of September 30, 2017 and December 31, 2016 and the movements for the periods then ended are as follows:

			Distributor &
	Patents &		Customer
	Trademarks		Relationships		Totals
*Cost or Deemed Cost*
At December 31, 2016	$	2,626,996	$	1,270,639	$	3,897,635
Additions		-		-		-
Disposals		-		-		-
At September 30, 2017	$	2,626,996	$	1,270,639	$	3,897,635

*Accumulated Amortization*
At December 31, 2016	$	1,325,221	$	1,270,639	$	2,595,860
Amortization Charge		128,331		-		128,331
Disposals		-		-		-
At September 30, 2017	$	1,453,552	$	1,270,639	$	2,724,191

*Net Book Value*
At December 31, 2016	$	1,301,775	$	-	$	1,301,775
At September 30, 2017	$	1,173,444	$	-	$	1,173,444

Amortization expense totaled $42,777 and $128,331 during the three and nine months ended September 30, 2017 and $42,777 and $128,331 for the three and nine months ended September 30, 2016.

The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Period	Amount
2017	$	171,108
2018	$	171,108
2019	$	171,108
2020	$	171,108
2021	$	171,108